NEW

Rush Oak Park Hospital Adopts Surgical Workflow Technology, ExplORer Surgical, Increasing Team Confidence and Reducing OR Challenges

ExplORer Surgical, the only comprehensive intraoperative case support and workflow platform, has reinvented the way surgical support teams prepare and complete effective surgeries with two-way video for case support and remote proctoring to create a digitized playbook.

AORN Releases 2021 Guidelines for Perioperative Practice

The Association of periOperative Registered Nurses (AORN) has published the 2021 Guidelines for Perioperative Practice with six revised guidelines.

Masimo Announces iSirona Connectivity Hub

Masimo has announced the global launch of iSirona, a compact, versatile connectivity hub designed to maximize interoperability across the continuum of care.

DJO Acquires Trilliant Surgical

DJO LLC, a global provider of medical technologies to get and keep people moving, has announced the acquisition of Trilliant Surgical, a national provider of foot and ankle orthopedic implants.

ICU Medical Completes the Acquisition of Hospira Infusion Systems

ICU Medical Inc. has completed its acquisition of the Hospira Infusion Systems business from Pfizer Inc. The Hospira Infusion Systems business includes IV pumps, solutions, and devices that, when combined with the company’s existing businesses, makes ICU Medical one of the world’s leading pure-play infusion therapy companies.
“We are pleased that Hospira Infusion Systems is now part of ICU Medical and welcome our new Hospira colleagues to the ICU team. We look forward to working together to continue providing quality, innovation and value to our clinical customers worldwide,” said Vivek Jain, chairman and chief executive officer at ICU Medical.
The Hospira Infusion Systems acquisition complements ICU Medical’s existing business to create a company with a complete IV therapy product portfolio from solutions to pumps to non-dedicated infusion sets. In addition, the acquisition gives ICU Medical a significantly enhanced global footprint and platform for continued competitiveness and long-term growth. With an integrated product offering, the company now holds industry-leading positions in key segments and has access to the full U.S. infusion marketplace with a compelling product portfolio.
The company plans to announce full FY 2017 guidance on its Q4 Earnings call in late February.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X